Clinical Trials (Phase I)
Filter News
Found 12,403 articles
-
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
9/25/2018
Cerevance today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
-
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene ...
9/24/2018
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company's Duchenne... -
Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
9/24/2018
Oral presentation to include new data from ASPIRO out to 48-weeks of follow-up in the earliest treated patients in dose Cohort 1, and preliminary safety and efficacy data from the sentinel patient in dose Cohort 2
-
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
9/24/2018
Daiichi Sankyo Company announced that updated phase 1 safety and efficacy data for trastuzumab deruxtecan, an investigational HER2 were presented for a subgroup of patients with heavily pretreated HER2 mutated or HER2 expressing non-small cell lung cancer
-
Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer
9/24/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials,
-
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
9/21/2018
Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data from a phase Ib clinical trial (NCT02937116) that treated patients with neuroendocrine tumors
-
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Previously Treated Non-Small Cell Lung Cancer at Annual Meeting of the Chinese Society of Clinical Oncology
9/21/2018
Innovent Biologics, Inc. today presented clinical research data on cohort C at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).
-
Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million
9/20/2018
Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals. -
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab as the First-line Treatment for Patients with NSCLC at Annual Meeting of the Chinese Society of Clinical Oncology
9/20/2018
Innovent Biologics (Innovent), presented clinical trial data on cohort D of sintilimab clinical studies at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).
-
Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure
9/20/2018
Cardurion Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733
-
Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
9/20/2018
Compugen entitled to $7.8 million milestone payment
-
Exicure Announces Positive Phase 1 Results for its Lead Immuno-Oncology Asset
9/20/2018
First in human results demonstrate potent immune system activation with no serious adverse events or dose limiting toxicity
-
Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018
9/20/2018
Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients with locally advanced head and neck cancers
-
Cell Medica: First Neuroblastoma Patient Successfully Dosed with Innovative CAR Therapy Utilizing Natural Killer T Cells (CAR-NKT)
9/20/2018
Ground-breaking Phase 1 trial, GINAKIT2, part of Cell Medica’s collaboration with Baylor College of Medicine and Texas Children’s Hospital
-
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
9/20/2018
Oxurion NV announced today the enrollment of the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME).
-
Cardiac Dimensions Announces the Randomization of its First Patient in the U.S. Pivotal Trial – The CARILLON Trial
9/19/2018
Multi-Center Study to Evaluate Innovative Minimally Invasive Treatment for Functional Mitral Regurgitation
-
MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
9/19/2018
Oral presentation by trial’s Chief Investigator describes complete tumour responses reported in patients off-study when subsequently administered standard of care
-
First Patient Dosed in Initial Immunotherapy Combination Trial Utilizing CBT’s Proprietary Assets
9/19/2018
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
-
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
9/19/2018
Alector today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001
-
Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.